When we analyzed the abundance of gluconeogenesis and/or glycolysis markers in sections of complete tumors we found an unexpected upregulation of PCK2 at the tumor margins, compared to tumor centers, while for GLUT1 no preference was found. This evidence concerns the gene SLC2A1 and neoplasm.